Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Study of Clecigabine for Refractory Erythematotelangiectatic Rosacea
ChiCTR2600121050Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clecigabine in rosacea, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Flushing Assessment Scale Tool (FAST) at week 8. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
clecigabine
03
Conditions
rosacea
Beyond the preview
Go deeper on ChiCTR2600121050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121050.